Header Logo

RENATA FERRAROTTO

TitleAssistant Professor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. de Sousa LG, Ferrarotto R. B7-H4: A potential therapeutic target in adenoid cystic carcinoma. Oncotarget. 2024 Nov 22; 15:807-808. PMID: 39576662; PMCID: PMC11584030.
      Citations:    Fields:    
    2. Contrera KJ, Ferrarotto R, Gunn B, Su SY, Kies MS, Glisson BS, Garden AS, Roberts D, Hanba C, Hoff CO, El-Naggar A, Williams MD, Raza SM, DeMonte F, Chen MM, Chambers MS, Hanna EY. Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2024 Nov 12. PMID: 39531535.
      Citations:    Fields:    
    3. Bronk JK, Augustyn A, Mohamed ASR, David Fuller C, Garden AS, Moreno AC, Lee A, Morrison WH, Phan J, Reddy JP, Rosenthal DI, Spiotto MT, Frank SJ, Dadu R, Busaidy N, Zafereo M, Wang JR, Maniakas A, Ferrarotto R, Iyer PC, Cabanillas ME, Gunn GB. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiother Oncol. 2024 Nov 01; 202:110602. PMID: 39489425.
      Citations:    Fields:    
    4. de Moraes ATL, Dos Santos ES, Pedroso CM, Gomes RT, Ferrarotto R, Santos-Silva AR. Human oncogenic viruses: a focus on head and neck carcinogenesis: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2024 Oct 30. PMID: 39551637.
      Citations:    Fields:    
    5. Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL, Rare Tumor Initiative Team. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024 Oct 24. PMID: 39446377; PMCID: PMC11581602.
      Citations:    Fields:    
    6. Zhao J, Williams MD, Hernandez M, Kuang G, Goldberg H, Fan J, Ning J, Ferrarotto R, Esmaeli B. Prognostic Impact of Notch1 Intracellular Domain, P63, and c-MYC in Lacrimal Gland Adenoid Cystic Carcinoma. Invest Ophthalmol Vis Sci. 2024 Sep 03; 65(11):4. PMID: 39230995; PMCID: PMC11379087.
      Citations:    Fields:    Translation:Humans
    7. Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024 Sep 01; 10(9):1264-1271. PMID: 38990526.
      Citations:    Fields:    Translation:Humans
    8. Goodman CD, DeMonte F, Nguyen TP, Garden AS, Wang CH, Wang XA, Diao K, Lee A, Reddy J, Moreno A, Spiotto M, Fuller CD, Rosenthal D, Ferrarotto R, Raza SM, Su SY, Warner A, Hanna E, Phan J. A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma. Head Neck. 2025 Jan; 47(1):81-89. PMID: 39073252.
      Citations:    Fields:    
    9. Esmaeli B, Fan J, Goldberg H, Lu T, Gross ND, Akhave N, Sousa LG, Ferrarotto R. Immune checkpoint inhibitors with or without chemotherapy for orbital, conjunctival, and ocular adnexal squamous cell carcinoma. Can J Ophthalmol. 2024 Jul 20. PMID: 39043259.
      Citations:    Fields:    
    10. Karpinets TV, Mitani Y, Chang CC, Wu X, Song X, Flores II, McDaniel LK, Hoballah YM, Veguilla FJ, Ferrarotto R, Colbert LE, Ajami NJ, Jenq RR, Zhang J, Futreal AP, El-Naggar AK. Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers. Sci Rep. 2024 07 15; 14(1):16300. PMID: 39009605; PMCID: PMC11251153.
      Citations:    Fields:    Translation:HumansCells
    11. Tasoulas J, Schrank TP, Bharambe H, Mehta J, Johnson S, Divaris K, Hackman TG, Sheth S, Kirtane K, Hernandez-Prera JC, Chung CH, Yarbrough WG, Ferrarotto R, Issaeva N, Theocharis S, Amelio AL. Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites. Sci Rep. 2024 07 09; 14(1):15821. PMID: 38982149; PMCID: PMC11233590.
      Citations: 1     Fields:    Translation:Humans
    12. Goldberg H, Jiang X, Fan J, Zhao J, Ning J, Williams M, Frank S, Moreno A, Gunn B, Ferrarotto R, Esmaeli B. Lacrimal Gland Adenocarcinoma Clinicopathologic Features and Outcomes Compared With Those of Lacrimal Gland Adenoid Cystic Carcinoma. Ophthalmic Plast Reconstr Surg. 2024 Jul-Aug 01; 40(4):419-425. PMID: 38319188; PMCID: PMC11226383.
      Citations: 1     Fields:    Translation:Humans
    13. Hoff CO, Manzi J, Lazar Neto F, Ferrarotto R. Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2024 Jul 01; 150(7):587-597. PMID: 38814585; PMCID: PMC11140580.
      Citations:    Fields:    Translation:Humans
    14. Fan J, Goldberg H, Torres-Cabala CA, Stewart J, Nagarajan P, Debnam M, Crouse EC, Lu T, Ferrarotto R, Esmaeli B. Complete Response to Immunotherapy Using Pembrolizumab in a Patient With Conjunctival Squamous Cell Carcinoma With Nodal Metastasis. Ophthalmic Plast Reconstr Surg. 2024 Sep-Oct 01; 40(5):e171-e174. PMID: 38687306.
      Citations:    Fields:    Translation:Humans
    15. Hoff CO, Dal Lago EA, Siqueira JM, de Sousa LG, El-Naggar AK, Ahnert JR, Ferrarotto R. First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO Precis Oncol. 2024 Apr; 8:e2300633. PMID: 38579194; PMCID: PMC11018191.
      Citations:    Fields:    Translation:Humans
    16. Dal Lago EA, Sousa LG, Yang Z, Hoff CO, Bonini F, Sawyer M, Wang K, Lewis W, Wahid KA, Hanna EY, El-Naggar A, Fuller CD, Kundu S, Godoy M, Ferrarotto R. Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma. Oral Oncol. 2024 Apr; 151:106759. PMID: 38507991; PMCID: PMC11195296.
      Citations:    Fields:    Translation:Humans
    17. Goldfarb J, Fan J, de Sousa LG, Akhave N, Myers J, Goepfert R, Manisundaram K, Zhao J, Frank SJ, Moreno A, Ferrarotto R, Esmaeli B. Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas. Semin Ophthalmol. 2024 Mar 18; 1-7. PMID: 38500295; PMCID: PMC11408703.
      Citations:    Fields:    
    18. de Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol. 2024 Apr; 151:106747. PMID: 38460288.
      Citations: 1     Fields:    Translation:Humans
    19. Zhao J, Jiang X, Hanna E, Su SY, Moreno A, Gunn B, Frank SJ, Ferrarotto R, Ning J, Esmaeli B. Orbital and periocular complications in patients with sinonasal tumours with orbital invasion. Br J Ophthalmol. 2024 02 21; 108(3):465-470. PMID: 36707226; PMCID: PMC10372198.
      Citations:    Fields:    
    20. Reyes-Gibby CC, Qdaisat A, Ferrarotto R, Fadol A, Bischof JJ, Coyne CJ, Lipe DN, Hanna EY, Shete S, Abe JI, Yeung SJ. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors. Head Neck. 2024 03; 46(3):627-635. PMID: 38151809; PMCID: PMC10922978.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    21. Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. Oral Oncol. 2024 Feb; 149:106634. PMID: 38118249.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    22. Zhao Z, Frank SJ, Ning J, Zhao J, Jiang X, Wang XA, Schefler AC, Hanna E, Moreno A, Gunn B, Ferrarotto R, Esmaeli B. Visual outcome and ocular complications in patients with lacrimal gland carcinoma after eye-sparing surgery and adjuvant radiation therapy. Br J Ophthalmol. 2023 11 22; 107(12):1914-1919. PMID: 36229179; PMCID: PMC10097836.
      Citations:    Fields:    
    23. Siqueira JM, Mitani Y, Hoff CO, Bonini F, Guimaraes de Sousa L, Marques-Piubelli ML, Purushothaman A, Mitani M, Dai H, Lin SY, Spiotto MT, Hanna EY, McGrail DJ, El-Naggar AK, Ferrarotto R. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance. Mod Pathol. 2024 Jan; 37(1):100371. PMID: 38015043.
      Citations: 1     Fields:    Translation:Humans
    24. Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol. 2023 11; 24(11):1196-1205. PMID: 37875144.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    25. Contrera KJ, Ramesh U, Shakibai N, Su SY, Brahimaj B, Roberts D, Williams MD, Ferrarotto R, Phan J, Gunn GB, Raza S, DeMonte F, Hanna EY. Sinonasal NUT carcinoma: A consecutive case series and systematic review. Head Neck. 2024 01; 46(1):29-36. PMID: 37853958.
      Citations: 2     Fields:    Translation:Humans
    26. Brahimaj BC, Contrera KJ, Rubino F, Almeida RA, Ferrarotto R, Phan J, Su SY, Hanna EY, DeMonte F, Raza SM. Induction Chemotherapy for Sinonasal Tumors in Patients Presenting with Brain Invasion and/or Neurological Deficits. J Neurol Surg B Skull Base. 2024 Dec; 85(6):650-658. PMID: 39483161; PMCID: PMC11524726.
      Citations:    
    27. Locati LD, Ferrarotto R, Licitra L, Benazzo M, Preda L, Farina D, Gatta G, Lombardi D, Nicolai P, Vander Poorten V, Chua MLK, Vischioni B, Sanguineti G, Morbini P, Fonseca I, Sozzi D, Merlotti A, Orlandi E. Current management and future challenges in salivary glands cancer. Front Oncol. 2023; 13:1264287. PMID: 37795454; PMCID: PMC10546333.
      Citations:    
    28. Ferrarotto R, Nagarajan P, Maronge JM, Johnson JM, Rosenthal DI, Myers JN, Gross ND. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2023 09 01; 149(9):847-849. PMID: 37535378; PMCID: PMC10401391.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    29. Sousa LG, McGrail DJ, Lazar Neto F, Li K, Marques-Piubelli ML, Ferri-Borgogno S, Dai H, Mitani Y, Spardy Burr N, Cooper ZA, Kinneer K, Cortez MA, Lin SY, Bell D, El Naggar A, Burks J, Ferrarotto R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res. 2023 08 15; 29(16):3162-3171. PMID: 37256648; PMCID: PMC10526680.
      Citations: 1     Fields:    Translation:Humans
    30. Persson M, Andersson MK, Sahlin PE, Mitani Y, Brandwein-Weber MS, Frierson HF, Moskaluk C, Fonseca I, Ferrarotto R, Boecker W, Loening T, El-Naggar AK, Stenman G. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. J Pathol. 2023 11; 261(3):256-268. PMID: 37565350.
      Citations: 2     Fields:    Translation:HumansCells
    31. Zhang X, Gleber-Netto FO, Wang S, Jin KW, Yang DM, Gillenwater AM, Myers JN, Ferrarotto R, Pickering CR, Xiao G. A Deep Learning Onion Peeling Approach to Measure Oral Epithelium Layer Number. Cancers (Basel). 2023 Jul 31; 15(15). PMID: 37568707; PMCID: PMC10416878.
      Citations:    
    32. Baruch EN, Nagarajan P, Gleber-Netto FO, Rao X, Xie T, Akhter S, Adewale A, Shajedul I, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunaratne P, Goepfert RP, Khushalani N, Wang J, Watowich S, Calin GA, Migden MR, Vermeer P, D'Silva N, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo J, Myers JN, Gross ND, Amit M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq. 2023 Jul 18. PMID: 37503252; PMCID: PMC10371163.
      Citations:    
    33. Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK. Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2023 Jul 14; 29(14):2737. PMID: 37449360.
      Citations:    Fields:    
    34. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J, Le X. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer. 2023 07; 11(7). PMID: 37402581; PMCID: PMC10335483.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    35. Bonini F, de Sousa LG, Ferrarotto R. New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Emerg Drugs. 2023 12; 28(2):97-106. PMID: 37144289.
      Citations:    Fields:    Translation:Humans
    36. Wotman M, El-Naggar A, Ferrarotto R. Targeting human EGFR 2 (HER2) in salivary gland carcinoma. Expert Rev Anticancer Ther. 2023 06; 23(6):573-582. PMID: 37114470.
      Citations:    Fields:    Translation:Humans
    37. Bahig H, Ehab HY, Garden AS, Ng SP, Frank SJ, Nguyen T, Gunn GB, Rosenthal DI, Fuller CD, Ferrarotto R, Bell D, Su S, Phan J. Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience. Head Neck. 2023 07; 45(7):1692-1703. PMID: 37165701.
      Citations:    Fields:    Translation:Humans
    38. Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491. PMID: 36762947; PMCID: PMC10122263.
      Citations: 2     Fields:    Translation:Humans
    39. Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851. PMID: 36898078; PMCID: PMC10414730.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    40. Contrera KJ, Shakibai N, Su SY, Gule-Monroe MK, Roberts D, Brahimaj B, Williams MD, Ferrarotto R, Phan J, Gunn B, Raza S, DeMonte F, Hanna EY. Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg. 2023 08; 169(2):435-440. PMID: 36856048.
      Citations: 1     Fields:    Translation:Humans
    41. Zhang X, Gleber-Netto FO, Wang S, Martins-Chaves RR, Gomez RS, Vigneswaran N, Sarkar A, William WN, Papadimitrakopoulou V, Williams M, Bell D, Palsgrove D, Bishop J, Heymach JV, Gillenwater AM, Myers JN, Ferrarotto R, Lippman SM, Pickering CR, Xiao G. Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia. Cancer Med. 2023 03; 12(6):7508-7518. PMID: 36721313; PMCID: PMC10067069.
      Citations: 1     Fields:    Translation:Humans
    42. de Sousa LG, Lazar Neto F, Dal Lago EA, Sikora A, Hanna E, Moreno A, Phan J, Glisson BS, Bell D, Ferrarotto R. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol. 2023 03; 138:106311. PMID: 36702015.
      Citations: 1     Fields:    Translation:HumansCells
    43. William WN, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, Gillenwater AM, Wistuba II, Myers JN, Gold KA, Ferrarotto R, Hwu P, Davoli T, Lee JJ, Heymach JV, Papadimitrakopoulou VA, Lippman SM. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 2023 03 01; 129(5):714-727. PMID: 36597662; PMCID: PMC10508302.
      Citations:    Fields:    Translation:HumansCells
    44. Weissferdt A, Sepesi B, Ning J, Hermsen M, Ferrarotto R, Glisson B, Hanna E, Bell D. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Curr Oncol Rep. 2023 01; 25(1):1-10. PMID: 36422794.
      Citations:    Fields:    Translation:Humans
    45. Wagner VP, Vargas PA, Martins MD, Bingle CD, Bingle L, Ferrarotto R, Ferrarotto R. Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials. Crit Rev Oncol Hematol. 2023 Jan; 181:103886. PMID: 36427771.
      Citations: 1     Fields:    
    46. Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2022 10 27; 387(17):1557-1568. PMID: 36094839; PMCID: PMC9844515.
      Citations:    
    47. Ferrarotto R, Mishra V, Herz E, Yaacov A, Solomon O, Rauch R, Mondshine A, Motin M, Leibovich-Rivkin T, Davis M, Kaye J, Weber CR, Shen L, Pearson AT, Rosenberg AJ, Chen X, Singh A, Aster JC, Agrawal N, Izumchenko E. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022 08 05; 13(8):678. PMID: 35931701; PMCID: PMC9355983.
      Citations:    
    48. Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2022 08; 6:e2100504. PMID: 35977347; PMCID: PMC10530586.
      Citations:    
    49. McGrail DJ, Pili? PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022 11; 33(11):1204-1206. PMID: 35926816; PMCID: PMC10325933.
      Citations:    
    50. Persson M, Andersson MK, Mitani Y, Brandwein-Weber MS, Frierson HF, Moskaluk C, Fonseca I, Ferrarotto R, Boecker W, Loening T, El-Naggar AK, Stenman G. Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. Cancers (Basel). 2022 Jul 28; 14(15). PMID: 35954356; PMCID: PMC9367430.
      Citations:    
    51. de Sousa LG, Jovanovic K, Ferrarotto R. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments. Curr Treat Options Oncol. 2022 08; 23(8):1135-1150. PMID: 35854180.
      Citations:    Fields:    
    52. Taku N, Chronowski G, Brandon Gunn G, Morrison WH, Gross ND, Moreno AC, Ferrarotto R, Frank SJ, Fuller CD, Goepfert RP, Phan J, Lai SY, Reddy JP, Rosenthal DI, Garden AS. Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):1054-1062. PMID: 35504500; PMCID: PMC9288980.
      Citations:    Fields:    Translation:HumansCells
    53. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735. PMID: 35419587.
      Citations:    Fields:    
    54. Shah JP, Beitler JJ, Snyderman CH, Lund V, Piazza C, Guntinas-Lichius O, Rodrigo JP, Quer M, Shaha A, Homma A, Ferrarotto R, Lee AWM, Lee VHF, Rinaldo A, Ferlito A, L?pez F, M?kitie AA, Kowalski LP, Sanabria A. The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours. Adv Ther. 2022 06; 39(6):2379-2397. PMID: 35352310; PMCID: PMC9122878.
      Citations:    Fields:    Translation:Humans
    55. Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks J, Lin SY, Bell D, Ferrarotto R. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer. 2022 03; 10(3). PMID: 35241495; PMCID: PMC8896046.
      Citations:    Fields:    Translation:HumansCells
    56. de Sousa LG, Neto FL, Lin J, Ferrarotto R. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma. Curr Oncol Rep. 2022 05; 24(5):621-631. PMID: 35212920.
      Citations:    Fields:    Translation:Humans
    57. Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS, William W. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022 02; 10(2). PMID: 35193933; PMCID: PMC9066369.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    58. Lazar Neto F, Sousa LG, Lewis WE, Glisson B, Heymach JV, Tsao AS, Ferrarotto R. Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report. J Intensive Care Med. 2022 Aug; 37(8):1055-1059. PMID: 34787022.
      Citations:    Fields:    
    59. de Sousa LG, Ferrarotto R. Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert Rev Anticancer Ther. 2021 12; 21(12):1321-1331. PMID: 34689660.
      Citations:    Fields:    Translation:Humans
    60. Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, Lewis WE, Rivera MJ, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022 02 01; 128(3):509-518. PMID: 34661906.
      Citations:    Fields:    Translation:Humans
    61. Goldfarb JA, Ferrarotto R, Gross N, Goepfert R, Debnam JM, Gunn B, Nagarajan P, Esmaeli B. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol. 2023 03; 107(3):320-323. PMID: 34625433.
      Citations:    Fields:    
    62. Sousa LG, Lazar Neto F, Torman DK, Diaz EM, Rosenthal DI, Glisson BS, Bell D, Ferrarotto R. Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma: A single-center retrospective analysis. Head Neck. 2021 12; 43(12):3788-3795. PMID: 34524729; PMCID: PMC8595607.
      Citations:    Fields:    Translation:Humans
    63. Kiong KL, Bell D, Yao CM, Ferrarotto R, Lewis CM. Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Oral Oncol. 2021 11; 122:105520. PMID: 34521029.
      Citations: 1     Fields:    Translation:Humans
    64. Ferrarotto R, Anderson I, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, Pritchett Y, Morris SR, Malik RK, Csoszi T, Medgyasszay B, Garc?a-Campelo MR, Sanchez-Hernandez A. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Med. 2021 09; 10(17):5748-5756. PMID: 34405547; PMCID: PMC8419768.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    65. Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420. PMID: 34358340; PMCID: PMC10187975.
      Citations:    Fields:    Translation:Humans
    66. Abdelmeguid AS, Bell D, Roberts D, Ferrarotto R, Phan J, Su SY, Kupferman M, Raza S, DeMonte F, Hanna E. Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature. Laryngoscope. 2022 02; 132(2):290-297. PMID: 34272876.
      Citations: 2     Fields:    Translation:Humans
    67. Diao K, Nguyen TP, Moreno AC, Reddy JP, Garden AS, Wang CH, Tung S, Wang C, Wang XA, Rosenthal DI, Fuller CD, Gunn GB, Frank SJ, Morrison WH, Shah SJ, Lee A, Spiotto MT, Su SY, Ferrarotto R, Phan J. Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head Neck. 2021 11; 43(11):3331-3344. PMID: 34269492; PMCID: PMC8511054.
      Citations:    Fields:    Translation:Humans
    68. Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591. PMID: 34241781.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    69. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67. PMID: 34237343.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    70. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565. PMID: 34187851; PMCID: PMC8711237.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    71. Gunn GB, Garden AS, Ye R, Ausat N, Dahlstrom KR, Morrison WH, Fuller CD, Phan J, Reddy JP, Shah SJ, Mayo LL, Chun SG, Chronowski GM, Moreno AC, Myers JN, Hanna EY, Esmaeli B, Gillison ML, Ferrarotto R, Hutcheson KA, Chambers MS, Ginsberg LE, El-Naggar AK, Rosenthal DI, Zhu XR, Frank SJ. Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther. 2021; 8(1):108-118. PMID: 34285940; PMCID: PMC8270083.
      Citations:    
    72. Bahig H, Gunn BG, Garden AS, Ye R, Hutcheson K, Rosenthal DI, Phan J, Fuller CD, Morrison WH, Reddy JP, Ng SP, Gross ND, Sturgis EM, Ferrarotto R, Gillison M, Frank SJ. Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. Int J Part Ther. 2021; 8(1):213-222. PMID: 34285948; PMCID: PMC8270092.
      Citations:    
    73. Sherry AD, Pasalic D, Gunn GB, Fuller CD, Phan J, Rosenthal DI, Morrison WH, Sturgis EM, Gross ND, Gillison ML, Ferrarotto R, El-Naggar AK, Garden AS, Frank SJ. Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. Int J Part Ther. 2021; 8(1):234-247. PMID: 34285950; PMCID: PMC8270080.
      Citations:    
    74. Hanania AN, Zhang X, Gunn GB, Rosenthal DI, Garden AS, Fuller CD, Phan J, Reddy JP, Moreno A, Chronowski G, Shah S, Ausat N, Hanna E, Ferrarotto R, Frank SJ. Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. Int J Part Ther. 2021; 8(1):261-272. PMID: 34285952; PMCID: PMC8270094.
      Citations:    
    75. McGrail DJ, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY, Pili? PG. Reply to: 'Real-world prevalence across 159?872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et?al. Ann Oncol. 2021 09; 32(9):1194-1197. PMID: 34166757.
      Citations: 1     Fields:    Translation:Humans
    76. Taku N, Wang L, Garden AS, Rosenthal DI, Gunn GB, Morrison WH, Fuller CD, Phan J, Reddy JP, Moreno AC, Spiotto MT, Chronowski G, Shah SJ, Mayo LL, Gross ND, Ferrarotto R, Zhu XR, Zhang X, Frank SJ. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Curr Treat Options Oncol. 2021 06 04; 22(6):54. PMID: 34086150; PMCID: PMC8178129.
      Citations: 2     Fields:    Translation:HumansCells
    77. Karpinets TV, Mitani Y, Liu B, Zhang J, Pytynia KB, Sellen LD, Karagiannis DT, Ferrarotto R, Futreal AP, El-Naggar AK. Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations. Clin Cancer Res. 2021 07 15; 27(14):3960-3969. PMID: 34011559; PMCID: PMC8598082.
      Citations: 3     Fields:    Translation:Humans
    78. Aggarwal P, Goepfert RP, Garden AS, Garg N, Zaveri JS, Du XL, Swartz MD, Lai SY, Fuller CD, Ferrarotto R, Sturgis EM, Piller LB, Hutcheson KA. Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngol Head Neck Surg. 2021 05 01; 147(5):469-478. PMID: 33538759; PMCID: PMC7863016.
      Citations: 2     Fields:    Translation:Humans
    79. Abdelmeguid AS, Silver NL, Boonsripitayanon M, Glisson BS, Ferrarotto R, Gunn GB, Phan J, Gillenwater AM, Hanna EY. Role of induction chemotherapy for oral cavity squamous cell carcinoma. Cancer. 2021 09 01; 127(17):3107-3112. PMID: 33909292.
      Citations:    Fields:    Translation:Humans
    80. Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 2021 08; 31(8):1235-1243. PMID: 33599171; PMCID: PMC8420950.
      Citations: 6     Fields:    Translation:Humans
    81. Guo TW, Saiyed F, Yao CMKL, Kiong KL, Martinez J, Sacks R, Lee JJ, Moreno AC, Frank SJ, Rosenthal DI, Glisson BS, Ferrarotto R, Mott FE, Johnson FM, Myers JN. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer. 2021 08 15; 127(16):2916-2925. PMID: 33873251.
      Citations:    Fields:    Translation:Humans
    82. Ferrarotto R, Di Villeneuve L, Souza IL, Tolentino FDS, Schvartsman G. Corrigendum: Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Front Oncol. 2021; 11:669486. PMID: 33898325; PMCID: PMC8063728.
      Citations:    
    83. van Dijk LV, Mohamed ASR, Ferrarotto R, McCoy LA, Sharafi CS, Jones E, Steele K, Moreno AC, Lai SY, Garden AS, Myers JN, Rosenthal DI, Fuller CD, Hutcheson KA, MD Anderson Symptom Working Group. The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. Cancer. 2021 07 15; 127(14):2453-2464. PMID: 33788956; PMCID: PMC8359995.
      Citations: 1     Fields:    Translation:Humans
    84. McGrail DJ, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY, Pili? PG. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021 05; 32(5):661-672. PMID: 33736924; PMCID: PMC8053682.
      Citations: 121     Fields:    Translation:Humans
    85. Kiong KL, Yao CMKL, Lin FY, Bell D, Ferrarotto R, Weber RS, Lewis CM. Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes. Cancer. 2021 06 15; 127(12):1984-1992. PMID: 33631040.
      Citations: 1     Fields:    Translation:Humans
    86. Bell D, Rubin ML, Tetzlaff M, Hanna E, Lee JJ, Weber R, Phan J, Glisson BS, Ferrarotto R, Schvartsman G. The tumor immune contexture of salivary duct carcinoma. Head Neck. 2021 04; 43(4):1213-1219. PMID: 33576119.
      Citations: 3     Fields:    Translation:Humans
    87. Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603. PMID: 33522021.
      Citations: 1     Fields:    Translation:Humans
    88. Amit M, Liu C, Netto Gleber FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177. PMID: 33352413.
      Citations:    Fields:    Translation:Humans
    89. Christopherson KM, Moreno AC, Elgohari B, Gross N, Ferrarotto R, Mohamed ASR, Brandon Gunn G, Goepfert RP, Mott FE, Shah SJ, David Fuller C, Reddy JP, Frank SJ, Morrison WH, Phan J, Rosenthal DI, Garden AS. Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol. 2021 02; 113:105125. PMID: 33360375; PMCID: PMC9272675.
      Citations: 2     Fields:    Translation:Humans
    90. Amit M, Liu C, Gleber-Netto FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Baruch EN, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245. PMID: 33320343.
      Citations: 2     Fields:    Translation:Humans
    91. Dahlstrom KR, Song J, Thall PF, Fuller CD, Hutcheson KA, Johnson FM, Gunn GB, Phan J, Frank SJ, Morrison WH, Ferrarotto R, Rosenthal DI, Sturgis EM, Garden AS. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237. PMID: 33306202; PMCID: PMC8058232.
      Citations:    Fields:    Translation:Humans
    92. Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2021 02 01; 27(3):852-864. PMID: 33172898; PMCID: PMC7854509.
      Citations: 6     Fields:    Translation:HumansCells
    93. Hart LL, Ferrarotto R, Andric ZG, Beck JT, Subramanian J, Radosavljevic DZ, Zaric B, Hanna WT, Aljumaily R, Owonikoko TK, Verhoeven D, Xiao J, Morris SR, Antal JM, Hussein MA. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther. 2021 01; 38(1):350-365. PMID: 33123968; PMCID: PMC7854399.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    94. Liu W, Qdaisat A, Zhou S, Fuller CD, Ferrarotto R, Guo M, Lai SY, Cardoso R, Mohamed ASR, Lopez G, Narayanan S, van Dijk LV, Cohen L, Bruera E, Yeung SJ, Hanna EY. Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers. Head Neck. 2021 02; 43(2):613-621. PMID: 33094893; PMCID: PMC10359096.
      Citations:    Fields:    Translation:Humans
    95. Ferrarotto R, Di Villeneuve L, Souza IL, Tolentino FDS, Schvartsman G. Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Front Oncol. 2020; 10:580141. PMID: 33194707; PMCID: PMC7649804.
      Citations: 14     
    96. Liu W, Qdaisat A, Ferrarotto R, Fuller CD, Guo M, Meyer LA, Narayanan S, Lopez G, Cohen L, Bruera E, Hanna EY, Yeung SJ. Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation. Cancer. 2021 02 15; 127(4):528-534. PMID: 33085092; PMCID: PMC8884478.
      Citations:    Fields:    Translation:Humans
    97. Ng SP, Bahig H, Jethanandani A, Sturgis EM, Johnson FM, Elgohari B, Gunn GB, Ferrarotto R, Phan J, Rosenthal DI, Frank SJ, Fuller CD, Garden AS. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. Br J Cancer. 2021 02; 124(3):628-633. PMID: 33051590; PMCID: PMC7851392.
      Citations: 4     Fields:    Translation:HumansCells
    98. Hamza A, Ferrarotto R, Kaya D, Weber RS, Bell D. von Ebner's glands intercalated duct adenocarcinoma with PALB2 gene mutation. Ann Diagn Pathol. 2020 Dec; 49:151637. PMID: 33069082.
      Citations:    Fields:    Translation:Humans
    99. Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2). PMID: 33106386; PMCID: PMC7592253.
      Citations: 24     Fields:    Translation:HumansAnimals
    100. Choi KY, Amit M, Tam S, Bell D, Phan J, Garden AS, Williams MD, Ferrarotto R, El-Naggar AK, Raza SM, DeMonte F, Kupferman ME, Hanna EY, Su SY. Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope. 2021 05; 131(5):E1468-E1475. PMID: 32946597.
      Citations: 1     Fields:    Translation:Humans
    101. Bell D, Bell A, Ferrarotto R, Glisson B, Takahashi Y, Fuller G, Weber R, Hanna E. High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol. 2020 Dec; 49:151622. PMID: 32927372.
      Citations:    Fields:    Translation:HumansCells
    102. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404. PMID: 32761153; PMCID: PMC7411939.
      Citations: 35     Fields:    Translation:Humans
    103. Lee DY, Brayer KJ, Mitani Y, Burns EA, Rao PH, Bell D, Williams MD, Ferrarotto R, Pytynia KB, El-Naggar AK, Ness SA. Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma. Cancers (Basel). 2020 Aug 27; 12(9). PMID: 32867110; PMCID: PMC7565926.
      Citations: 1     
    104. Bagley AF, Garden AS, Reddy JP, Moreno AC, Frank SJ, Rosenthal DI, Morrison WH, Gunn GB, Fuller CD, Shah SJ, Ferrarotto R, Sturgis EM, Gross ND, Phan J. Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020 11; 42(11):3326-3335. PMID: 32776401; PMCID: PMC7722120.
      Citations: 5     Fields:    Translation:Humans
    105. Kiong KL, Lin FY, Yao CMKL, Guo T, Ferrarotto R, Weber RS, Lewis CM. Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer. Cancer. 2020 10 01; 126(19):4304-4314. PMID: 32706401.
      Citations: 1     Fields:    Translation:Humans
    106. Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463. PMID: 32608142; PMCID: PMC7543335.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    107. Ford JR, Rubin ML, Frank SJ, Ning J, Debnam JM, Bell D, El-Naggar A, Ferrarotto R, Esmaeli B. Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. Br J Ophthalmol. 2021 06; 105(6):768-774. PMID: 32680839.
      Citations: 1     Fields:    Translation:Humans
    108. Le X, Ferrarotto R, Wise-Draper T, Gillison M. Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. J Natl Compr Canc Netw. 2020 07; 18(7):899-906. PMID: 32634775.
      Citations: 8     Fields:    Translation:Humans
    109. Stieb S, Perez-Martinez I, Mohamed ASR, Rock S, Bajaj N, Deshpande TS, Zaid M, Garden AS, Goepfert RP, Cardoso R, Ferrarotto R, Reddy JP, Phan J, Morrison WH, Rosenthal DI, Koay EJ, Frank SJ, Fuller CD, Gunn GB, MD Anderson Head and Neck Cancer Symptom Working Group. The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clin Transl Radiat Oncol. 2020 Sep; 24:71-78. PMID: 32642562; PMCID: PMC7334797.
      Citations: 4     
    110. MD Anderson Head and Neck Surgery Treatment Guidelines Consortium, Consortium members, Maniakas A, Jozaghi Y, Zafereo ME, Sturgis EM, Su SY, Gillenwater AM, Gidley PW, Lewis CM, Diaz E, Goepfert RP, Kupferman ME, Gross ND, Hessel AC, Pytynia KB, Nader ME, Wang JR, Lango MN, Kiong KL, Guo T, Zhao X, Yao CMKL, Appelbaum E, Alpard J, Garcia JA, Terry S, Flynn JE, Bauer S, Fournier D, Burgess CG, Wideman C, Johnston M, You C, De Luna R, Joseph L, Diersing J, Prescott K, Heiberger K, Mugartegui L, Rodriguez J, Zendehdel S, Sellers J, Friddell RA, Thomas A, Khanjae SJ, Schwarzlose KB, Chambers MS, Hofstede TM, Cardoso RC, Wesson RA, Won A, Otun AO, Gombos DS, Al-Zubidi N, Hutcheson KA, Gunn GB, Rosenthal DI, Gillison ML, Ferrarotto R, Weber RS, Hanna EY, Myers JN, Lai SY. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020 06; 42(6):1194-1201. PMID: 32342541; PMCID: PMC7267348.
      Citations: 21     Fields:    Translation:HumansCellsPHPublic Health
    111. Pasalic D, Ludmir EB, Allen PK, Thaker NG, Chapman BV, Hanna EY, Su SY, Ferrarotto R, Glisson BS, Reddy JP, Brandon Gunn G, Fuller CD, Phan J, Rosenthal DI, Morrison WH, Garden AS, Frank SJ. Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266. PMID: 32417351.
      Citations: 4     Fields:    Translation:Humans
    112. Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Phan J, Cardenas C, Ferrarotto R, Frank SJ, Rosenthal DI, Garden AS. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Adv Radiat Oncol. 2020 Sep-Oct; 5(5):929-935. PMID: 33083655; PMCID: PMC7557124.
      Citations: 2     
    113. Kiong KL, Guo T, Yao CMKL, Gross ND, Hanasono MM, Ferrarotto R, Rosenthal DI, Myers JN, Hanna EY, Lai SY. Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. Head Neck. 2020 06; 42(6):1179-1186. PMID: 32459061.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    114. Ng SP, Cardenas CE, Elhalawani H, Pollard C, Elgohari B, Fang P, Meheissen M, Guha-Thakurta N, Johnson JM, Kamal M, Garden AS, Reddy JP, Su SY, Ferrarotto R, Frank SJ, Brandon Gunn G, Moreno AC, Rosenthal DI, Fuller CD, Phan J, Bahig H. Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. Phys Imaging Radiat Oncol. 2020 Apr; 14:1-5. PMID: 33458306; PMCID: PMC7807720.
      Citations: 4     
    115. Grant SR, Hutcheson KA, Ye R, Garden AS, Morrison WH, Rosenthal DI, Brandon Gunn G, Fuller CD, Phan J, Reddy JP, Moreno AC, Lewin JS, Sturgis EM, Ferrarotto R, Frank SJ. Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol. 2020 07; 148:133-139. PMID: 32361662; PMCID: PMC9815953.
      Citations: 4     Fields:    Translation:Humans
    116. Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman DK, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora AG, Gillison ML, Glisson BS, Gross ND. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020 07 01; 26(13):3211-3219. PMID: 32269052; PMCID: PMC8362306.
      Citations: 19     Fields:    Translation:HumansCells
    117. Garden AS, Kamal M, Mohamed ASR, Frank SJ, Lewin JS, Lai SY, Morrison WH, Phan J, Ferrarotto R, Rosenthal DI, Hutcheson KA, Fuller CD, Gunn GB. Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head Neck. 2020 08; 42(8):2137-2144. PMID: 32212359; PMCID: PMC7519845.
      Citations: 1     Fields:    Translation:Humans
    118. Stieb S, Mohamed ASR, Deshpande TS, Harp J, Greiner B, Garden AS, Goepfert RP, Cardoso R, Ferrarotto R, Phan J, Reddy JP, Morrison WH, Rosenthal DI, Frank SJ, Fuller CD, Brandon Gunn G, MD Anderson Head and Neck Cancer Symptom Working Group. Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time? Clin Transl Radiat Oncol. 2020 May; 22:98-105. PMID: 32373720; PMCID: PMC7191583.
      Citations: 2     
    119. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704; PMCID: PMC7078933.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    120. Tam S, Yao CMKL, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135. PMID: 31804658; PMCID: PMC6902183.
      Citations: 5     Fields:    Translation:Humans
    121. Choi JS, Sansoni ER, Lovin BD, Lindquist NR, Phan J, Mayo LL, Ferrarotto R, Su SY. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review. Ann Otol Rhinol Laryngol. 2020 May; 129(5):517-522. PMID: 31875405.
      Citations: 10     Fields:    Translation:Humans
    122. Bahig H, Ng SP, Pollard C, Nguyen TP, Gunn GB, Rosenthal DI, Fuller CD, Frank SJ, Garden AS, Reddy JP, Morrison WH, Ferrarotto R, Hanna EY, DeMonte F, Su SY, Phan J. A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497. PMID: 31868271; PMCID: PMC9673230.
      Citations:    Fields:    Translation:Humans
    123. Pestana RC, Becnel M, Rubin ML, Torman DK, Crespo J, Phan J, Hanna E, Bell D, Glisson BS, Johnson JM, Lee JJ, Ferrarotto R. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020 02; 101:104523. PMID: 31864957.
      Citations: 12     Fields:    Translation:Humans
    124. Mitani Y, Lin SH, Pytynia KB, Ferrarotto R, El-Naggar AK. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clin Cancer Res. 2020 03 01; 26(5):1175-1184. PMID: 31772120; PMCID: PMC7056500.
      Citations: 4     Fields:    Translation:HumansCells
    125. Hutcheson KA, Warneke CL, Yao CMKL, Zaveri J, Elgohari BE, Goepfert R, Hessel AC, Kupferman ME, Lai SY, Fuller CD, Gunn GB, Garden AS, Johnson F, Ferrarotto R, Lewin JS, Gross ND, MD Anderson Head and Neck Cancer Symptom Working Group. Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2019 Nov 01; 145(11):1053-1063. PMID: 31556933; PMCID: PMC6763976.
      Citations: 11     Fields:    
    126. Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R, Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG. Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. Oral Oncol. 2020 03; 102:104440. PMID: 31648864; PMCID: PMC7260859.
      Citations: 1     Fields:    Translation:HumansCells
    127. Ng SP, Pollard C, Kamal M, Ayoub Z, Garden AS, Bahig H, Gunn GB, Frank SJ, Skinner HD, Phan J, Berends J, Morrison WH, Johnson JM, Ferrarotto R, Sturgis EM, Mohamed ASR, Lai SY, Fuller CD, Rosenthal DI. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019; 3:22. PMID: 31583278; PMCID: PMC6764977.
      Citations: 7     
    128. Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237. PMID: 31484556; PMCID: PMC6727581.
      Citations: 25     Fields:    Translation:Humans
    129. Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, Broaddus R, Weber RS, El-Naggar AK. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020 Feb; 476(2):295-305. PMID: 31423558.
      Citations: 7     Fields:    Translation:Humans
    130. Bagley AF, Ye R, Garden AS, Gunn GB, Rosenthal DI, Fuller CD, Morrison WH, Phan J, Sturgis EM, Ferrarotto R, Wu R, Liu AY, Frank SJ. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020 01; 142:133-139. PMID: 31431373; PMCID: PMC8457365.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    131. Shah M, Jomaa MK, Ferrarotto R, Yeung SJ, Hanna EY, Reyes-Gibby CC. Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head Neck. 2019 11; 41(11):4036-4050. PMID: 31414560.
      Citations: 2     Fields:    Translation:Humans
    132. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043. PMID: 31319771; PMCID: PMC6707029.
      Citations: 36     Fields:    Translation:Humans
    133. Ng SP, Wang H, Pollard C, Nguyen T, Bahig H, Fuller CD, Gunn GB, Garden AS, Reddy JP, Morrison WH, Shah S, Rosenthal DI, Frank SJ, Guha-Thakurta N, Ferrarotto R, Hanna EY, Su SY, Phan J. Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base. 2020 Dec; 81(6):638-644. PMID: 33381367; PMCID: PMC7755504.
      Citations: 1     
    134. Saluja K, Ravishankar S, Ferrarotto R, Zhu H, Pytynia KB, El-Naggar AK. Ectopic ACTH Production and Cushing's Syndrome in a Patient with Parotid Acinic Cell Carcinoma with High-Grade Transformation: Tumor Context and Clinical Implications. Head Neck Pathol. 2020 Jun; 14(2):562-569. PMID: 31363907; PMCID: PMC7235128.
      Citations: 2     Fields:    Translation:Humans
    135. Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, Elamin Y, Thakar SD, Nagarajan P, Esmaeli B. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg. 2019 Jul/Aug; 35(4):350-353. PMID: 30365473.
      Citations: 2     Fields:    Translation:Humans
    136. Bell AH, Prieto VG, Ferrarotto R, Goepfert RP, Myers JN, Weber R, Bell D. Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis. Ann Diagn Pathol. 2019 Aug; 41:14-23. PMID: 31128548.
      Citations:    Fields:    Translation:Humans
    137. Hamza A, Roberts D, Su S, Weber RS, Bell D, Ferrarotto R. PD-L1 expression by immunohistochemistry in salivary duct carcinoma. Ann Diagn Pathol. 2019 Jun; 40:49-52. PMID: 30978575; PMCID: PMC6599643.
      Citations: 6     Fields:    Translation:Humans
    138. Ng SP, Pollard C, Berends J, Ayoub Z, Kamal M, Garden AS, Bahig H, Cantor SB, Schaefer AJ, Ajayi T, Gunn GB, Frank SJ, Skinner H, Phan J, Morrison WH, Ferrarotto R, Johnson JM, Mohamed ASR, Lai SY, Hessel AC, Sturgis EM, Weber RS, Fuller CD, Rosenthal DI. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019 06 01; 125(11):1823-1829. PMID: 30748005; PMCID: PMC7234834.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    139. Tyler MA, Mohamed ASR, Smith JB, Aymard JM, Fuller CD, Phan J, Frank SJ, Ferrarotto R, Kupferman ME, Hanna EY, Gunn GB, Su SY. Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope. 2020 01; 130(1):86-93. PMID: 30706478.
      Citations: 4     Fields:    Translation:Humans
    140. Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, Ferrarotto R, Glisson B, Kupferman ME, Roberts DB, Su SY, Raza SM, DeMonte F, Hanna EY. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512. PMID: 30615549; PMCID: PMC6380524.
      Citations: 23     Fields:    Translation:Humans
    141. Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):67-73. PMID: 30267032; PMCID: PMC6439768.
      Citations: 144     Fields:    Translation:HumansCellsCTClinical Trials
    142. Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME, Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Dec; 2. PMID: 35135166; PMCID: PMC9797231.
      Citations: 1     Fields:    
    143. Ibrahim MY, Nunez MI, Harun N, Lee JJ, El-Naggar AK, Ferrarotto R, Wistuba I, Myers J, Glisson BS, William WN. PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. Head Neck. 2019 03; 41(3):615-622. PMID: 30556200; PMCID: PMC6382518.
      Citations: 3     Fields:    Translation:HumansCells
    144. Bell D, Ferrarotto R, Schvartsman G, Pinto NA. Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease. Head Neck. 2019 01; 41(1):239-247. PMID: 30552848.
      Citations: 5     Fields:    Translation:Humans
    145. Mays AC, Hanna EY, Ferrarotto R, Phan J, Bell D, Silver N, Mulcahy CF, Roberts D, Abdelmeguid ASA, Fuller CD, Frank SJ, Raza SM, Kupferman ME, DeMonte F, Su SY. Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. Head Neck. 2018 12; 40(12):2596-2605. PMID: 30447126.
      Citations: 3     Fields:    Translation:Humans
    146. Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer. 2018 Sep 19; 18(1):903. PMID: 30231854; PMCID: PMC6148797.
      Citations: 6     Fields:    Translation:HumansCells
    147. Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK, Saintigny P. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018 09 15; 124(18):3693-3705. PMID: 30289966; PMCID: PMC6176717.
      Citations: 10     Fields:    Translation:HumansCells
    148. Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hobbs B, Loyer EM, Kopetz S, Hoff PM. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst. 2018 08 01; 110(8):888-894. PMID: 29346573.
      Citations: 9     Fields:    Translation:Humans
    149. Sagiv O, Nagarajan P, Ferrarotto R, Kandl TJ, Thakar SD, Glisson BS, Altan M, Esmaeli B. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019 06; 103(6):775-780. PMID: 30021814.
      Citations: 7     Fields:    Translation:Humans
    150. Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68. PMID: 29996921; PMCID: PMC6042271.
      Citations: 64     Fields:    Translation:Humans
    151. Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 07 01; 29(7):1561-1568. PMID: 29726923.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    152. Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018 07; 28(7):945-951. PMID: 29742974; PMCID: PMC6425982.
      Citations: 38     Fields:    Translation:Humans
    153. Kamal M, Mohamed ASR, Volpe S, Zaveri J, Barrow MP, Gunn GB, Lai SY, Ferrarotto R, Lewin JS, Rosenthal DI, Jethanandani A, Meheissen MAM, Mulder SL, Cardenas CE, Fuller CD, Hutcheson KA, MD Anderson Head, Neck Cancer Symptom Working Group. Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. Radiother Oncol. 2018 09; 128(3):442-451. PMID: 29961581; PMCID: PMC6595477.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    154. Ferrarotto R, William WN, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90. PMID: 29909907.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    155. Multidisciplinary Larynx Cancer Working Group, Mulcahy CF, Mohamed ASR, Kanwar A, Hutcheson KA, Ghosh A, Vock D, Weber RS, Lai SY, Gunn GB, Zafereo M, Morrison WH, Ferrarotto R, Garden AS, Rosenthal DI, Fuller CD. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018 09; 40(9):2060-2069. PMID: 29756307; PMCID: PMC6131035.
      Citations: 6     Fields:    Translation:Humans
    156. Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck. 2018 08; 40(8):1676-1684. PMID: 29570891; PMCID: PMC6105373.
      Citations: 3     Fields:    Translation:HumansCells
    157. Kamal M, Ng SP, Eraj SA, Rock CD, Pham B, Messer JA, Garden AS, Morrison WH, Phan J, Frank SJ, El-Naggar AK, Johnson JM, Ginsberg LE, Ferrarotto R, Lewin JS, Hutcheson KA, Cardenas CE, Zafereo ME, Lai SY, Hessel AC, Weber RS, Gunn GB, Fuller CD, Mohamed ASR, Rosenthal DI. Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol. 2018 04; 79:1-8. PMID: 29598944; PMCID: PMC5880303.
      Citations: 2     Fields:    Translation:Humans
    158. Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Res. 2018; 7. PMID: 31583077; PMCID: PMC6753603.
      Citations: 13     Fields:    
    159. Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Ferrarotto R, Frank SJ, Skinner HD, Rosenthal DI, Garden AS. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018 04 01; 124(7):1415-1427. PMID: 29338089; PMCID: PMC11362832.
      Citations: 4     Fields:    Translation:Humans
    160. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87. PMID: 29161986; PMCID: PMC6425981.
      Citations: 37     Fields:    Translation:Humans
    161. Mays AC, Bell D, Ferrarotto R, Phan J, Roberts D, Fuller CD, Frank SJ, Raza SM, Kupferman ME, DeMonte F, Hanna EY, Su SY. Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope. 2018 06; 128(6):1274-1280. PMID: 29226334.
      Citations: 2     Fields:    Translation:Humans
    162. MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Brandon Gunn G. Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 11 23; 12(1):186. PMID: 29169353; PMCID: PMC5701383.
      Citations:    Fields:    
    163. William WN, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, Glisson B, Kim ES. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017 Dec; 77(6):1110-1113.e2. PMID: 28964539; PMCID: PMC5685879.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    164. Ferrarotto R, Heymach JV. Taking it up a NOTCH: a novel subgroup of ACC is identified. Oncotarget. 2017 Oct 10; 8(47):81725-81726. PMID: 29137213; PMCID: PMC5669839.
      Citations: 3     Fields:    
    165. MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Gunn GB. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150. PMID: 28888224; PMCID: PMC5591495.
      Citations: 13     Fields:    Translation:Humans
    166. Su SY, Bell D, Ferrarotto R, Phan J, Roberts D, Kupferman ME, Frank SJ, Fuller CD, Gunn GB, Kies MS, Glisson BS, Hanna EY. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679. PMID: 28561956.
      Citations: 18     Fields:    Translation:Humans
    167. Shiao JC, Mohamed ASR, Messer JA, Hutcheson KA, Johnson JM, Enderling H, Kamal M, Warren BW, Pham B, Morrison WH, Zafereo ME, Hessel AC, Lai SY, Kies MS, Ferrarotto R, Garden AS, Schomer DF, Gunn GB, Phan J, Frank SJ, Beadle BM, Weber RS, Lewin JS, Rosenthal DI, Fuller CD. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 08; 39(8):1609-1620. PMID: 28464542; PMCID: PMC5511768.
      Citations: 4     Fields:    Translation:Humans
    168. Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 05; 27(5):672-681. PMID: 28068873; PMCID: PMC5802249.
      Citations: 44     Fields:    Translation:Humans
    169. Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360. PMID: 27870570; PMCID: PMC5456373.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    170. Schvartsman G, Ferrarotto R, Massarelli E. Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol. 2016 Nov; 8(6):460-473. PMID: 27800034; PMCID: PMC5066544.
      Citations: 12     
    171. Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. J Oncol Pract. 2016 06; 12(6):511-8. PMID: 27288464.
      Citations: 42     Fields:    Translation:Humans
    172. Ferrarotto R, Heymach JV, Glisson BS. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Curr Opin Oncol. 2016 May; 28(3):195-200. PMID: 26974847.
      Citations: 13     Fields:    Translation:Humans
    173. Mauzo SH, Ferrarotto R, Bell D, Torres-Cabala CA, Tetzlaff MT, Prieto VG, Aung PP. Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. J Clin Pathol. 2016 May; 69(5):382-90. PMID: 26818033.
      Citations: 5     Fields:    Translation:Humans
    174. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Rashid A, Yao JC, Kopetz S, Dasari A, Hoff PM. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15(2):e1-7. PMID: 26810202; PMCID: PMC4885752.
      Citations: 16     Fields:    Translation:Humans
    175. Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686. PMID: 26597303; PMCID: PMC4818738.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    176. Massarelli E, Ferrarotto R, Glisson BS. New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic. Clin Cancer Res. 2015 Sep 01; 21(17):3821-8. PMID: 26330505.
      Citations: 6     Fields:    Translation:HumansCells
    177. Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP--framework, overview, and design principles. Chin Clin Oncol. 2015 Sep; 4(3):36. PMID: 26408303.
      Citations: 13     Fields:    Translation:Humans
    178. Bell D, Ferrarotto R, Fox MD, Roberts D, Hanna EY, Weber RS, El-Naggar AK. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther. 2015; 16(6):834-8. PMID: 25923130; PMCID: PMC4622840.
      Citations: 1     Fields:    Translation:Humans
    179. Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Vauthey JN, Vilar E, Maru D, Kopetz S, Pereira AA, Rego JF, Hoff PM. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8. PMID: 25535726; PMCID: PMC4453646.
      Citations: 40     Fields:    Translation:Humans
    180. Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res. 2014 Dec 15; 20(24):6570-81. PMID: 25316813; PMCID: PMC4268116.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    181. Ferrarotto R, Gold KA. Afatinib in the treatment of head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2014 Jan; 23(1):135-43. PMID: 24266694.
      Citations: 11     Fields:    Translation:Humans
    182. Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, Hoff PM, Ferrarotto R. Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors. 2013; 5(3):e35. PMID: 24179647; PMCID: PMC3804810.
      Citations: 9     
    183. Ferrarotto R, Hoff PM. Antiangiogenic drugs for colorectal cancer: exploring new possibilities. Clin Colorectal Cancer. 2013 Mar; 12(1):1-7. PMID: 22763196.
      Citations: 7     Fields:    Translation:HumansAnimals
    184. Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM, Ferrarotto R. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer. 2012 Apr; 48(6):820-6. PMID: 22330318.
      Citations: 5     Fields:    Translation:Humans
    185. Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz S, Ferrarotto R. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer. 2011 Sep; 10(3):178-82. PMID: 21855039.
      Citations: 21     Fields:    Translation:Humans
    186. Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM, Rodrigues CA. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis. 2010 Jul; 30(1):67-78. PMID: 20140479.
      Citations: 9     Fields:    Translation:Humans
    187. Anaplastic thyroid carcinoma. Journal of Oncology Practice. 12:511-518.
    188. Checkpoint inhibitors in lung cancer. Therapeutic Advances in Medical Oncology. 8:460-473.
    189. Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. Clinical Cancer Research. 22:1674-1686.
    190. Non-Small Cell Lung Cancers (NSCLC) with Mutations in BRAF. 557-563.
    191. Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles. Radiotherapy and Oncology. 118:304-314.
    192. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Current Opinion in Oncology.
    193. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biology and Therapy. 16:834-838.
    194. High-Grade Neuroendocrine Colorectal Carcinomas. Clinical Colorectal Cancer.
    195. Best strategy in the approach of advanced colorectal cancer. Current Colorectal Cancer Reports. 8:177-185.
    196. Paclitaxel induced chronic fibrosing interstitial pneumonitis. Oncology Reviews. 4:101-106.
    FERRAROTTO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (397)
    Explore
    _
    Co-Authors (193)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _